利血平与戊脉安对豚鼠左心房的作用比较

利血平具有浓度依赖性负性肌力作用。对异丙肾上腺素量-效反应的影响与戊脉安相似,不同于β-受体竞争性拮抗剂心得安.对Ca~(2+)量-效反应的影响与戊脉安相似,表现为非竞争性拮抗作用,还具有频率依赖性负性肌力反应.结果说明利血平对豚鼠左心房肌的作用与戊脉安相似,可能具有Ca~(2+)拮抗作用.     

蛇床子素对大鼠离体子宫平滑肌收缩性能的影响

蛇床子素和维拉帕米对缩宫素、ＫＣｌ、高Ｋ＋除极化后Ｃａ２＋诱导大鼠离休子宫平滑肌收缩均产生抑制作用，对ＣａＣｌ２累积量效曲线均呈非竞争性拮抗效应，ｐＤ＇２（拮抗多数）分别为３．９±０．１５和７．４５±０．１；１００μｍｏｌ／Ｌ蛇床子素和０．０８μｍｏｌ／Ｌ维拉帕米显著抑制缩宫素诱导依赖细胞内Ｃａ２＋收缩反应，对依赖细胞外Ｃａ２＋的收缩均无明显影响。提示蛇床子素对子宫平滑肌的抑制作用类似维拉帕米，与拮抗Ｃａ２＋有关，且主要通过抑制平滑肌细胞膜上电位依赖性Ｃａ２＋通道和影响胞内Ｃａ２＋释放所致。     

高血压治疗的浅谈

高血压是危害人类健康的常见病和多发病。它既可以造成严重的心、脑、肾等重要脏器的损害,又是动脉硬化的重要危险因素。本文就高血压的定义、分类、分期、诊断、治疗及高血压的管理等作了简要论述,以帮助广大的科技人员提高对该病的防治知识。     

钙拮抗剂尼群地平的反相高效液相色谱分析及其在家兔体内的分布

对兔血浆及组织器官中钙拮抗剂尼群地平的分析方法进行了研究，建立了反相高效液相色谱（RP-HPLC）的内标测定法。样品在弱碱性条件下经环已烷-异丙醇（96．5：3．5）提取，用YWGC18反相柱，以地尔硫作内标，甲醇：50mmol／L磷酸盐缓冲液（70：30）pH6．8为流动相，UV236nm检测。方法最低检测限约为10ng，血药浓度在21．6～216μg／L之间，尼群地平的量与其峰面积比值之间，线性关系良好，回归方程为Y＝0．00672X－0．013，r＝0．9958。方法回收率95．4％～98．1％，RSD＜4．63％。　用该分析方法测定了家兔口服尼群地平2h后在主要脏器体液中的分布。     

The clinical analysis of secondary hypertension patients

Objective To analyze the situation of secondary hypertension caused by different etiology and its treatment status so as to improve its treatment. Methods Totally 580 patients with secondary hypertension selected with strict criteria were divided into 4 groups in accordance with the etiology. The data were dealt with SPSS 13.0. We analyzed the sex, age, systolic pressure, diastolic pressure and positive incidence of family history of all the secondary hypertension patients in each group, and compared their usage of every unilateral preparation. Results The average age of renal parenchymal disease was more advanced than that of adrenal disease and other diseases. The administration of diuretics and angiotensin-converting enzyme inhibitor (ACEI) in renal parenchymal disease group, αβ receptor blocking agents and calcium antagonists in kidney-artery disease group, a antagonists in adrenal disease and compound antihyportensive agents in other diseases groups all affected advantage of the ratio. Conclusion Diuretics and ACEI are suitable for hypertension caused by renal parenchymal disease, αβ receptor blocking agents and calcium antagonists are suitable for that caused by kidney artery disease, but a receptor blocking agents are suitable for that caused by adrenal disease.